Nilsson K, Klevebro F, Sunde B, Rouvelas I, Lindblad M, Szabo E, Halldestam I, Smedh U, Wallner B, Johansson J, Johnsen G, Aahlin EK, Johannessen HO, Alexandersson von Döbeln G, Hjortland GO, Wang N, Shang Y, Borg D, Quaas A, Bartella I, Bruns C, Schröder W, Nilsson M (2023)
Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre randomised controlled NeoRes II trial
Ann Oncol (in press)
DOI 10.1016/j.annonc.2023.08.010, PubMed 37657554

Niyoteka S, Seban RD, Rouhi R, Scarsbrook A, Genestie C, Classe M, Carré A, Sun R, La Greca Saint-Esteven A, Chargari C, McKenna J, McDermott G, Malinen E, Tanadini-Lang S, Guckenberger M, Guren MG, Lemanski C, Deutsch E, Robert C (2023)
A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers
Eur J Nucl Med Mol Imaging (in press)
DOI 10.1007/s00259-023-06320-2, PubMed 37632562

Nilsson MP, Undseth C, Albertsson P, Eidem M, Havelund BM, Johannsson J, Johnsson A, Radu C, Serup-Hansen E, Spindler KL, Zakrisson B, Guren MG, Kronborg C (2023)
Nordic anal cancer (NOAC) group consensus guidelines for risk-adapted delineation of the elective clinical target volume in anal cancer
Acta Oncol, 1-10 (in press)
DOI 10.1080/0284186X.2023.2240490, PubMed 37504978